APA (7th ed.) Citation

M, K., Z, R., Y, G., G, H., H, L., J, Z., . . . JM, L. (2025). Transarterial chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma (LEAP-012): A multicentre, randomised, double-blind, phase 3 study. Lancet (London, England), 405(10474), 203. https://doi.org/10.1016/S0140-6736(24)02575-3

Chicago Style (17th ed.) Citation

M, Kudo, et al. "Transarterial Chemoembolisation Combined with Lenvatinib Plus Pembrolizumab Versus Dual Placebo for Unresectable, Non-metastatic Hepatocellular Carcinoma (LEAP-012): A Multicentre, Randomised, Double-blind, Phase 3 Study." Lancet (London, England) 405, no. 10474 (2025): 203. https://doi.org/10.1016/S0140-6736(24)02575-3.

MLA (9th ed.) Citation

M, Kudo, et al. "Transarterial Chemoembolisation Combined with Lenvatinib Plus Pembrolizumab Versus Dual Placebo for Unresectable, Non-metastatic Hepatocellular Carcinoma (LEAP-012): A Multicentre, Randomised, Double-blind, Phase 3 Study." Lancet (London, England), vol. 405, no. 10474, 2025, p. 203, https://doi.org/10.1016/S0140-6736(24)02575-3.